Pharma Cooperation Code Transparency Report Methodological Note. Pfizer Switzerland

Transcription

1 Pharma Cooperation Code Transparency Report 2017 Methodological Note Pfizer Switzerland

2 1. Table of Content 2. INTRODUCTION PFIZER ACTIVITIES PER EFPIA/SCIENCEINDUSTRIES CATEGORY DEFINITION OF THE TRANSFERS OF VALUE/PECUNIARY BENEFITS... 6 Page 2 of 7

3 2. Introduction We regularly work with healthcare professionals (HCPs) and healthcare organisations (HCOs) who advise us on a range of topics such as medicines development, the role of a medicine in a patient treatment pathway; health economics and clinical best practice. These working relationships are essential to gaining the real-world information we need in order to deliver treatment choices that improve the health of patients and to share information that may be relevant to clinical decision making. We want people to know, and understand, what we do and how we do it. We are committed to transparency about how we operate as a business and about the relationships we have with HCPs and HCOs. Sharing information about these relationships in a straightforward and open way will, we hope, help explain the critical value these relationships bring to patient management. We believe that transparency is essential to building and maintaining confidence in us and in our medicines and strongly support the work being done by The European Federation of Pharmaceutical Industries and Associations (EFPIA) to improve transparency across the pharmaceutical industry. On 24 June 2013, the European Federation of Pharmaceutical Industries and Associations (EFPIA) adopted the new EFPIA Disclosure Code. On that basis, scienceindustries as the member association of EFPIA in Switzerland drew up the Pharma Cooperation Code (PCC). The EFPIA Disclosure Code and PCC provide a common basis for reporting across Europe in relation to transfers of value (ToVs). For more information on these Codes please visit: or Pfizer Switzerland will disclose ToVs of 2017 according to PCC latest at the end of June 2018 on the Pfizer Switzerland Homepage. This report discloses all the transfers of value made to Health Care Professionals (HCPs) and Health Care Organisations (HCOs) resident in Switzerland in This methodological note presents some of the key aspects of how the transfers of value are categorized and in what format they are disclosed. Please be informed that according to the decision made by the Pharma-Code Commission in April 2018, Pfizer Switzerland decided not to disclose any transfer of values to international organizations based in Switzerland with focus on non-profit services in the health sector (for example; WHO, UNHCR, IFRC, GABI etc.). These are specialized institutions for which disclosure of transfer of values under the PCC disclosure code does not seem reasonable in view of the sense and purpose of the Transparency Initiative. The respective organizations disclose potential cooperation directly. Page 3 of 7

4 3. Pfizer activities per EFPIA category The following table defines what activities are reported in which PCC category and subcategory. EFPIA category Donations and Grants (HCOs only) Contribution to Cost of Events Fee for services and consultancy EFPIA subcategory n/a Sponsorship agreements (HCOs only) Registration fees Travel & Accommodation Fees Activities Charitable contributions Business Donations Educational grants (e.g. fellowships, courses provided by a HCO where the Pfizer does not select the individual HCPs participating) Sponsoring of speakers/faculty which by nature of purpose and funding are classified under educational grants Placement of a brand logo in a conference program or invitation communication in exchange for supporting the program Funding an event in return for a display booth Funding an event in exchange for advertising space Other advertisement space (in paper, electronic or other format) Satellite symposia at a congress Any other activity qualified as Corporate Sponsorship according Pfizer s Anti-Corruption Policies Sponsoring of speaker/faculty and sponsoring courses provided by an HCO which are qualified as Corporate Sponsorship according Pfizer s Anti-Corruption Policies Fees paid for the HCP/HCO to attend events not organised by Pfizer Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking) Accommodation Speaker engagements Advisory Boards* Study-related engagements Preceptorships Post-marketing surveillance studies Medical writing Data analysis Development of education materials General consulting / advising Speaker training if linked to a speaker engagement Any other activity which qualifies as General Consultancy according to Pfizer s Anti-Corruption Policies Related expenses Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking) Accommodation Page 4 of 7

5 Research and Development Transfers of Value ** n/a Clinical Trials Data Monitoring Committees related to studies Non Interventional Studies Investigators Initiated Research (IIR) Clinical & Research Collaboration * excluding Data Monitoring Committees related to studies which are disclosed in aggregate under R&D ** aggregated disclosure Page 5 of 7

6 4. Definition of the Transfers of Value/Pecuniary Benefit This section outlines some key aspects of how the transfers of value are defined. Definition of Healthcare Professionals (HCPs) Physicians, dentists and pharmacists who are working in particular in a practice or hospital, together with pharmacists active in retail businesses, and persons who are authorised by Swiss law on therapeutic products, to prescribe, deliver or use prescription-only medicinal products for humans. Definition of Healthare Organsations (HCOs) Institutions, organisations, associations or other groups of healthcare professionals which provide healthcare services or consultancy tasks or other services in healthcare (e.g. hospitals, clinics, foundations, universities or other educational establishments, scientific societies or professional associations, community practices or networks, but not patient organisations). Which transfers of value/pecuniary benefits are disclosed? In cash, as non-cash contributions, donations, grants or payments made either directly or indirectly in some other form for consultancy tasks or services, research and development, advertising, sales or other purposes, always in connection with medicinal products available on prescription-only. Direct ToVs are those which a pharmaceutical company provides directly for a particular recipient. Indirect ToVs are those which a third party (e.g. supplier, agent, partner, subsidiary company or foundation) provides for a recipient in the name or on behalf of a pharmaceutical company, the identity of the pharmaceutical company being known or recognizable to the recipient. Timing of transfers of value: This report discloses all ToVs whose transaction date falls within the year The transaction date is defined as the payment date in the financial system. In the case of meetings, it is the last day of the meeting. Transfer of Value date: January 1, 2017 December 31, 2017 Direct ToV: Indirect ToV: Payment date ERP-System Reporting date is the date of event (last day of the event in case of multi-days events) Transfer of Value in case of partial attendances or cancellation: Cancellation Fees are not reported but ToV in case of partially attending an event is disclosed. Multi-year contracts: Where contracts are valid for more than one year, each individual ToV is captured and disclosed in the corresponding reporting period. Consent to disclose transfers of value: Pfizer asks HCPs and HCOs consent to the disclosure of the ToVs made to them. We do our best effort to advocate for transparency and convince to provide consent. Page 6 of 7

7 If recipients consent to disclosure, the sum of all ToVs to that HCP or HCO during the reporting period is disclosed under their name. Which tranfers of value/pecuniary benefits are disclosed aggregated? ToVs in connection with Research & Development such as planning or implementation of (i) a non-clinical study (defined in OECD s principles of good laboratory practice), (ii) a clinical trial or (iii) a non-intervention study that involves collecting patient data from healthcare personnel, as well as in-service education (in accordance to Pharma Code Section 333) and ToVs with unavailable consent. Over-the-counter medicines (OTC): OTC medicines are out of scope for this report. Transfers of value from Pfizer legal entities in other countries (cross border ToVs): This report includes ToVs to HCPs and HCOs resident in Switzerland. This includes all ToVs (direct and indirect) made by any Pfizer affiliates in the 33 European countries included in the EFPIA disclosure code. For non EFPIA countries, Pfizer will do their best effort to collect and disclose direct payments made by Pfizer affiliates. Currency: ToVs are reported in CHF. ToVs made in a different currency were converted to CHF when this report was created. The Pfizer standard exchange rates for the day of payment were applied. Value Added Tax (VAT): Pfizer Switzerland will disclose all ToVs at gross value (incl. VAT) if subject to VAT. Valuation of in kind donations: Pfizer Switzerland will disclose all kind of donations at fair market value. Country Unique Identifier: Pfizer Switzerland is using Cegedim One Key ID to identify HCPs and HCOs. Zurich, April 2018 Page 7 of 7